New data reveal that GLP-1 weight loss medications like Ozempic, Wegovy, and Mounjaro are becoming more popular in the local market, reported TimesLive (10 April 2026).
According to the data 13% of South Africans are either already using or actively considering these medications, while 63% of the population has never heard of these drugs at all.
“These glucagon-like peptide-1 receptor agonists work by mimicking gut hormones to regulate blood sugar and suppress appetite. They were originally designed for type 2 diabetes but have become global sensations for weight management.”
High cost remains a barrier for the wider population. However, prices are expected to decrease as generic versions is expected to expand access and significantly reduce costs
“For those in the healthcare industry, the message is clear. The ‘ripple effect’ of these medications will eventually reshape demand across multiple Fast-Moving Consumer Goods (FMCG) categories. Brands and healthcare providers must adapt to a consumer base that is becoming more focused on functional health and protein-rich diets.”